{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:15:57Z","timestamp":1791918957131,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1124\/dmd.123.001446","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T19:55:15Z","timestamp":1693338915000},"page":"1536-1546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacokinetics and Absorption, Distribution, Metabolism and Excretion of RGLS4326 in Mouse and Monkey, an Anti\u2013miR-17 Oligonucleotide for the Treatment of Polycystic Kidney Disease"],"prefix":"10.1016","volume":"51","author":[{"given":"Amin","family":"Kamel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tate","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaiah","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001446_bib1","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2174\/138920008786485065","article-title":"Plasma\/serum protein binding determinations","volume":"9","author":"Banker","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.123.001446_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1124\/dmd.123.001446_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000189504","article-title":"Distribution of the cellular uptake of phosphorothioate oligodeoxynucleotides in the rat kidney in vivo","volume":"75","author":"Carome","year":"1997","journal-title":"Nephron"},{"key":"10.1124\/dmd.123.001446_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/biomedicines9030303","article-title":"Oligonucleotide-Based Therapies for Renal Diseases","volume":"9","author":"Cart\u00f3n-Garc\u00eda","year":"2021","journal-title":"Biomedicines"},{"key":"10.1124\/dmd.123.001446_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003205","article-title":"MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways","volume":"4","author":"Chau","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1124\/dmd.123.001446_bib6","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.123.001446_bib7","unstructured":"Clark T, Weng Y, Salatto C, Stanton R, Dullea R, Giragossian C, Awwad M (2011). 96-Well Equilibrium Dialysis Followed by a Rapid Fluorescence Based Assay for Determining Plasma Protein Binding of Oligonucleotides, AAPS National Biotechnology Conference, Poster # M1050."},{"key":"10.1124\/dmd.123.001446_bib8","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-021-24799-x","article-title":"Extracellular vesicles and exosomes generated from cystic renal epithelial cells promote cyst growth in autosomal dominant polycystic kidney disease","volume":"12","author":"Ding","year":"2021","journal-title":"Nat Commun"},{"key":"10.1124\/dmd.123.001446_bib9","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/dmd.123.001446_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2165\/00003088-200645080-00003","article-title":"Lack of pharmacokinetic interaction for ISIS 113715, a 2\u2032-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone","volume":"45","author":"Geary","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001446_bib11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev.biochem.73.011303.073908","article-title":"Mechanisms of site-specific recombination","volume":"75","author":"Grindley","year":"2006","journal-title":"Annu Rev Biochem"},{"key":"10.1124\/dmd.123.001446_bib12","doi-asserted-by":"crossref","first-page":"14395","DOI":"10.1038\/ncomms14395","article-title":"microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism","volume":"8","author":"Hajarnis","year":"2017","journal-title":"Nat Commun"},{"key":"10.1124\/dmd.123.001446_bib13","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1681\/ASN.2014040354","article-title":"Identification of Biomarkers for PKD1 Using Urinary Exosomes","volume":"26","author":"Hogan","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.123.001446_bib14","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1681\/ASN.2008060564","article-title":"Characterization of PKD protein-positive exosome-like vesicles","volume":"20","author":"Hogan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.123.001446_bib15","series-title":"Current Perspectives in microRNAs (miRNA)","first-page":"1","article-title":"Structures of microRNA precursors","author":"Kozlowski","year":"2008"},{"key":"10.1124\/dmd.123.001446_bib17","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun"},{"key":"10.1124\/dmd.123.001446_bib18","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1007\/s11095-010-0156-0","article-title":"A direct comparison of anti-microRNA oligonucleotide potency","volume":"27","author":"Lennox","year":"2010","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.123.001446_bib19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/15476286.2018.1445959","article-title":"Anti-miRNA oligonucleotides: A comprehensive guide for design","volume":"15","author":"Lima","year":"2018","journal-title":"RNA Biol"},{"key":"10.1124\/dmd.123.001446_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/oli.2004.14.299","article-title":"Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury","volume":"14","author":"Masarjian","year":"2004","journal-title":"Oligonucleotides"},{"key":"10.1124\/dmd.123.001446_bib21","doi-asserted-by":"crossref","first-page":"10765","DOI":"10.1073\/pnas.1301693110","article-title":"miR-17\u223c92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease","volume":"110","author":"Patel","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.123.001446_bib22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0022-3565(25)20966-1","article-title":"Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake","volume":"279","author":"Sawai","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.123.001446_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1755-8794-1-41","article-title":"A high confidence, manually validated human blood plasma protein reference set","volume":"1","author":"Schenk","year":"2008","journal-title":"BMC Med Genomics"},{"key":"10.1124\/dmd.123.001446_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/6716","article-title":"Crystal structure of a phospholipase D family member","volume":"6","author":"Stuckey","year":"1999","journal-title":"Nat Struct Biol"},{"key":"10.1124\/dmd.123.001446_bib25","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s11033-009-9861-3","article-title":"MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation","volume":"37","author":"Sun","year":"2010","journal-title":"Mol Biol Rep"},{"key":"10.1124\/dmd.123.001446_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ncb0309-228","article-title":"Many roads to maturity: microRNA biogenesis pathways and their regulation","volume":"11","author":"Winter","year":"2009","journal-title":"Nat Cell Biol"},{"key":"10.1124\/dmd.123.001446_bib27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.106.012401","article-title":"Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100","volume":"35","author":"Yu","year":"2007","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:06:09Z","timestamp":1739955969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624010882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0090955624010882"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001446","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and Absorption, Distribution, Metabolism and Excretion of RGLS4326 in Mouse and Monkey, an Anti\u2013miR-17 Oligonucleotide for the Treatment of Polycystic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}